



FROM: Rebecca Rousselle, CIP
Emory University IRB

TO: Jeremy Sarnat, ScD
Principal Investigator

CC: Hunter Eric Envir & occup Health
Greenwald Robert Envir & occup Health
Wongtrakool Cherry MedPulm

DATE: May 11, 2009

RE: **Notification of Full Board Approval**
IRB00018855
The Atlanta Commuters Exposure Study

This is your notification that your above referenced study was reviewed and approved pending minor changes under the Full Board review process by Committee A3 on **4/29/2009**. This approval became effective after all pending issues were addressed on **5/7/2009**. This approval is effective until **4/28/2010**. Thereafter, continued approval is contingent upon the submission of a renewal form that must be reviewed and approved by the IRB prior to the expiration date of this study.

A partial waiver of HIPAA authorization for identifying eligible asthmatic subjects is included with this approval.

Any reportable events (serious adverse events, breaches of confidentiality, protocol deviation or protocol violations) or issues resulting from this study should be reported immediately to the IRB and to the sponsoring agency (if any). Any amendments (changes to any portion of this research study including but not limited to protocol or informed consent changes) must have IRB approval before being implemented.

All correspondence and inquiries concerning this research study must include the IRB ID, the name of the Principal Investigator and the Study Title.

Sincerely,

Rebecca Rousselle, CIP
Lead Research Protocol Analyst
This letter has been digitally signed